Demographics, comorbidities and therapy for all patients
| All | IL-17i | IL-17i+MTX | TNFi | TNFi+MTX | JAKi | JAKi+MTX | MTX | |
| Patients (n) | 92 | 19 | 5 | 27 | 4 | 18 | 6 | 13 |
| Age (years) | 50 (39–56) | 42 (36–53) | 37 (32–38) | 51 (42–56) | 58 (54–61) | 50 (43–56) | 55 (49–59) | 54 (37–64) |
| Female sex | 46 (50.0%) | 6 (31.6%) | 3 (60.0%) | 10 (37.0%) | 3 (75.0%) | 13 (72.2%) | 3 (50.0%) | 8 (61.5%) |
| BMI | 28 (24–31) | 28 (25–30) | 27 (24–28) | 29 (24–32) | 27 (26–37) | 26 (22–32) | 31 (28–35) | 27 (23–30) |
| Smoker | 29 (31.5%) | 13 (68.4%) | 1 (20.0%) | 17 (63.0%) | 0 (0.0%) | 5 (27.8%) | 1 (16.7%) | 3 (23.1%) |
| RA | 36 (39.1%) | 0 (0.0%) | 0 (0.0%) | 3 (11.1%) | 2 (50.0%) | 14 (77.8%) | 5 (83.3%) | 12 (92.3%) |
| axSpA | 34 (37.0%) | 11 (57.9%) | 0 (0.0%) | 21 (77.8%) | 0 (0.0%) | 2 (11.1%) | 0 (0.0%) | 0 (0.0%) |
| PsA | 22 (23.9%) | 8 (42.1%) | 5 (100.0%) | 3 (11.1%) | 2 (50.0%) | 2 (11.1%) | 1 (16.7%) | 1 (7.7%) |
| DAS28 | 2.28 (1.54–3.00) | 1.93 (0.70–2.59) | 1.55 (0.49–2.83) | 2.85 (2.47–2.89) | 2.62 (2.09–3.34) | 2.45 (1.71–3.57) | 1.42 (1.18–1.91) | 2.38 (1.66–2.86) |
| BASDAI | 3.5 (2.0–6.0) | 3.4 (2.2–6.1) | NA | 5.2 (2.6–6.0) | NA | 4.9 (2.5–5.4) | NA | 1.4 (1.4–1.4) |
| CRP (mg/dL) | 0.2 (0.1–0.3) | 0.2 (0.1–0.4) | 0.1 (0.1–0.1) | 0.2 (0.1–0.3) | 0.7 (0.2–2.8) | 0.2 (0.1–0.3) | 0.2 (0.1–0.2) | 0.2 (0.1–0.4) |
| Patients with concomitant GC (n) | 13 (14.1%) | 1 (5.3%) | 1 (20.0%) | 0 (0.0%) | 0 (0.0%) | 5 (27.8%) | 3 (50.0%) | 3 (23.1%) |
| Prednisolone dosage (mg) | 5.0 (2.5–5.0) | 5.0 (5.0–5.0) | 3.0 (3.0–3.0) | 5.0 (2.5–5.0) | 2.0 (2.0–4.0) | 5.0 (4.0–5.0) | ||
| Time since diagosis (years) | 5.0 (2.0–10.0) | 5.5 (4.25–10) | 11.0 (10.0–12.0) | 6 (2–11) | 13.0 (4–25.0) | 6.5 (4–10.25) | 6.0 (4.5–9.0) | 1.5 (1.0–2.0) |
| Prime | ||||||||
| AZ1222 (AstraZeneca) | 4 (4.3%) | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) | 0 (0.0%) | 0 (0.0%) | 2 (15.4%) |
| mRNA-1273 (Moderna) | 69 (75.0%) | 17 (89.5%) | 5 (100.0%) | 20 (74.1%) | 2 (50.0%) | 16 (88.9%) | 6 (100.0%) | 3 (23.1%) |
| BNT162b2 mRNA (Pfizer/BioNTech) | 19 (20.7%) | 1 (5.3%) | 0 (0.0%) | 7 (25.9%) | 1 (25.0%) | 2 (11.1%) | 0 (0.0%) | 8 (61.5%) |
| Boost | ||||||||
| mRNA-1273 (Moderna) | 69 (75.0%) | 17 (89.5%) | 5 (100.0%) | 20 (74.1%) | 2 (50.0%) | 16 (88.9%) | 6 (100.0%) | 3 (23.1%) |
| BNT162b2 mRNA (Pfizer/BioNTech) | 23 (25.0%) | 2 (10.5%) | 0 (0.0%) | 7 (25.9%) | 2 (50.0%) | 2 (11.1%) | 0 (0.0%) | 10 (76.9%) |
| Comorbidities | ||||||||
| None | 54 (58.7%) | 14 (73.7%) | 5 (100.0%) | 13 (48.1%) | 2 (50.0%) | 9 (50.0%) | 5 (83.3%) | 6 (46.2%) |
| Hypertension | 23 (25.0%) | 4 (21.1%) | 0 (0.0%) | 6 (22.2%) | 1 (25.0%) | 7 (38.9%) | 0 (0.0%) | 5 (38.5%) |
| Heart failure | 4 (4.3%) | 1 (5.3%) | 0 (0.0%) | 2 (7.4%) | 0 (0.0%) | 1 (5.6%) | 0 (0.0%) | 0 (0.0%) |
| Lung disease | 12 (13.0%) | 0 (0.0%) | 0 (0.0%) | 6 (22.2%) | 1 (25.0%) | 2 (11.1%) | 0 (0.0%) | 3 (23.1%) |
| Diabetes mellitus | 8 (8.7%) | 2 (10.5%) | 0 (0.0%) | 2 (7.4%) | 1 (25.0%) | 1 (5.6%) | 1 (16.7%) | 1 (7.7%) |
| Osteoporosis | 3 (3.3%) | 1 (5.3%) | 0 (0.0%) | 1 (3.7%) | 0 (0.0%) | 1 (5.6%) | 0 (0.0%) | 0 (0.0%) |
For quantitative variables, data are provided as median (IQR). For categorical variables the count (% frequency) is provided.
axSpA, axial spondyloathritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; CRP, C reactive protein; DAS28, Disease Activity Score 28; GC, glucocorticoid; i, inhibitor; IL, interleukin; JAK, Janus kinase; MTX, methotrexate; NA, not available; PsA, psoriatic arthritis; RA, rheumatoid arthritis.